CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Risperidone +2 moredrug
Likely dose
Risperidone 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01786239
NCT01786239N/ACompleted
CompareCT.gov

Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment

Delbert Robinson·interventional·Posted Feb 7, 2013·Updated Feb 1, 2017

In Brief

A clinical study evaluating Risperidone, Omega-3 capsules, and 1 other intervention for Schizophrenia and 4 related conditions. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychosis NOS
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH), National Alliance for Research on Schizophrenia and Depression

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 7, 2013
Enrollment StartMay 1, 2013
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.4 years ago

Interventions

Risperidonedrug

The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.

Omega-3 capsulesdrug

The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.

Placebodrug

The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.